Carlyle-backed life sciences investor launches $1.5bn clinical trials fund

Abingworth, a UK-based life sciences investor backed by Carlyle, is raising up to $1.5bn for clinical trials and royalty partnerships with pharmaceutical companies. Recent collaborations with Gilead Sciences and Teva demonstrate the fund’s focus on funding late-stage trials for promising drugs. Abingworth’s successful track record in phase-three trials, coupled with the current demand for new medicines, positions the fund as an attractive option for pharma companies seeking to maximize drug development opportunities.

Full Article